NO753203L - - Google Patents
Info
- Publication number
- NO753203L NO753203L NO753203A NO753203A NO753203L NO 753203 L NO753203 L NO 753203L NO 753203 A NO753203 A NO 753203A NO 753203 A NO753203 A NO 753203A NO 753203 L NO753203 L NO 753203L
- Authority
- NO
- Norway
- Prior art keywords
- receptor
- hormone
- sample
- reagent
- hcg
- Prior art date
Links
- 102000011022 Chorionic Gonadotropin Human genes 0.000 claims description 146
- 108010062540 Chorionic Gonadotropin Proteins 0.000 claims description 146
- 229940084986 human chorionic gonadotropin Drugs 0.000 claims description 146
- 229940088597 hormone Drugs 0.000 claims description 133
- 239000005556 hormone Substances 0.000 claims description 133
- 238000000034 method Methods 0.000 claims description 116
- 230000035935 pregnancy Effects 0.000 claims description 93
- 102000003946 Prolactin Human genes 0.000 claims description 81
- 229940097325 prolactin Drugs 0.000 claims description 81
- 108010057464 Prolactin Proteins 0.000 claims description 80
- 238000012360 testing method Methods 0.000 claims description 74
- 239000003153 chemical reaction reagent Substances 0.000 claims description 58
- 230000027455 binding Effects 0.000 claims description 40
- 210000000170 cell membrane Anatomy 0.000 claims description 39
- 241001465754 Metazoa Species 0.000 claims description 34
- 108010073521 Luteinizing Hormone Proteins 0.000 claims description 32
- 102000009151 Luteinizing Hormone Human genes 0.000 claims description 32
- 229940040129 luteinizing hormone Drugs 0.000 claims description 32
- 210000004246 corpus luteum Anatomy 0.000 claims description 31
- 210000001124 body fluid Anatomy 0.000 claims description 19
- 239000010839 body fluid Substances 0.000 claims description 19
- 230000002285 radioactive effect Effects 0.000 claims description 18
- 210000002700 urine Anatomy 0.000 claims description 18
- 101000687438 Homo sapiens Prolactin Proteins 0.000 claims description 16
- 210000004369 blood Anatomy 0.000 claims description 14
- 239000008280 blood Substances 0.000 claims description 14
- 230000005855 radiation Effects 0.000 claims description 14
- 239000000463 material Substances 0.000 claims description 11
- 210000001672 ovary Anatomy 0.000 claims description 11
- 241000894007 species Species 0.000 claims description 11
- 241000124008 Mammalia Species 0.000 claims description 10
- 210000002966 serum Anatomy 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 9
- 210000000056 organ Anatomy 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 6
- 241001494479 Pecora Species 0.000 claims description 5
- 241000283073 Equus caballus Species 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 3
- 229910052740 iodine Inorganic materials 0.000 claims description 3
- 239000011630 iodine Substances 0.000 claims description 3
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 claims 1
- XMLNCADGRIEXPK-KUMOIWDRSA-M chembl2146143 Chemical compound [Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N+]2(C)C)C(=O)C(CO)C1=CC=CC=C1 XMLNCADGRIEXPK-KUMOIWDRSA-M 0.000 claims 1
- 108020003175 receptors Proteins 0.000 description 87
- 102000005962 receptors Human genes 0.000 description 87
- 239000000523 sample Substances 0.000 description 48
- 210000001519 tissue Anatomy 0.000 description 24
- 230000002159 abnormal effect Effects 0.000 description 17
- 238000009597 pregnancy test Methods 0.000 description 17
- 230000016087 ovulation Effects 0.000 description 16
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 13
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 13
- 229940028334 follicle stimulating hormone Drugs 0.000 description 13
- 230000002611 ovarian Effects 0.000 description 13
- 238000010998 test method Methods 0.000 description 13
- 230000000984 immunochemical effect Effects 0.000 description 12
- 241000700159 Rattus Species 0.000 description 11
- 238000003127 radioimmunoassay Methods 0.000 description 11
- 241000282412 Homo Species 0.000 description 10
- 230000035931 haemagglutination Effects 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 238000001514 detection method Methods 0.000 description 9
- 238000005259 measurement Methods 0.000 description 9
- 241000283690 Bos taurus Species 0.000 description 8
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 8
- 229930006000 Sucrose Natural products 0.000 description 8
- 206010000210 abortion Diseases 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 239000005720 sucrose Substances 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 7
- 238000000691 measurement method Methods 0.000 description 7
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- 102000002265 Human Growth Hormone Human genes 0.000 description 6
- 108010000521 Human Growth Hormone Proteins 0.000 description 6
- 239000000854 Human Growth Hormone Substances 0.000 description 6
- 231100000176 abortion Toxicity 0.000 description 6
- 229940098773 bovine serum albumin Drugs 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000004816 latex Substances 0.000 description 6
- 229920000126 latex Polymers 0.000 description 6
- 230000035945 sensitivity Effects 0.000 description 6
- 206010000234 Abortion spontaneous Diseases 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 208000000995 spontaneous abortion Diseases 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 101000611570 Bos taurus Prolactin Proteins 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 102000011923 Thyrotropin Human genes 0.000 description 4
- 108010061174 Thyrotropin Proteins 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000002513 implantation Methods 0.000 description 4
- 230000003821 menstrual periods Effects 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 230000036470 plasma concentration Effects 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 210000004291 uterus Anatomy 0.000 description 4
- 206010000242 Abortion threatened Diseases 0.000 description 3
- 102000003864 Human Follicle Stimulating Hormone Human genes 0.000 description 3
- 108010082302 Human Follicle Stimulating Hormone Proteins 0.000 description 3
- 108010023244 Lactoperoxidase Proteins 0.000 description 3
- 102000045576 Lactoperoxidases Human genes 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 102000004576 Placental Lactogen Human genes 0.000 description 3
- 108010003044 Placental Lactogen Proteins 0.000 description 3
- 239000000381 Placental Lactogen Substances 0.000 description 3
- 229920005654 Sephadex Polymers 0.000 description 3
- 239000012507 Sephadex™ Substances 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 208000005985 Threatened Abortion Diseases 0.000 description 3
- 230000004520 agglutination Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000001493 electron microscopy Methods 0.000 description 3
- 238000002523 gelfiltration Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 229940057428 lactoperoxidase Drugs 0.000 description 3
- 238000011551 log transformation method Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000027758 ovulation cycle Effects 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 230000009870 specific binding Effects 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 108010039627 Aprotinin Proteins 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 238000001135 Friedman test Methods 0.000 description 2
- 102000006771 Gonadotropins Human genes 0.000 description 2
- 108010086677 Gonadotropins Proteins 0.000 description 2
- 208000032749 Pregnancy Diseases 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000006957 competitive inhibition Effects 0.000 description 2
- 230000037029 cross reaction Effects 0.000 description 2
- 230000009260 cross reactivity Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 201000003511 ectopic pregnancy Diseases 0.000 description 2
- 230000002357 endometrial effect Effects 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000004720 fertilization Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000001456 gonadotroph Effects 0.000 description 2
- 239000002622 gonadotropin Substances 0.000 description 2
- 229940094892 gonadotropins Drugs 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000029849 luteinization Effects 0.000 description 2
- 230000005906 menstruation Effects 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 210000002826 placenta Anatomy 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 229940108519 trasylol Drugs 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000599 Acromegaly Diseases 0.000 description 1
- 206010058897 Adnexa uteri mass Diseases 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 241000269350 Anura Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- -1 J12^ Chemical compound 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 206010034268 Pelvic prolapse Diseases 0.000 description 1
- 206010035104 Pituitary tumour Diseases 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 108010002519 Prolactin Receptors Proteins 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- COQLPRJCUIATTQ-UHFFFAOYSA-N Uranyl acetate Chemical compound O.O.O=[U]=O.CC(O)=O.CC(O)=O COQLPRJCUIATTQ-UHFFFAOYSA-N 0.000 description 1
- 206010046782 Uterine enlargement Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 210000004198 anterior pituitary gland Anatomy 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000008275 binding mechanism Effects 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 239000007978 cacodylate buffer Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 238000007705 chemical test Methods 0.000 description 1
- 238000013098 chemical test method Methods 0.000 description 1
- VDQQXEISLMTGAB-UHFFFAOYSA-N chloramine T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 description 1
- 238000009535 clinical urine test Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 230000002254 contraceptive effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- OGGXGZAMXPVRFZ-UHFFFAOYSA-M dimethylarsinate Chemical compound C[As](C)([O-])=O OGGXGZAMXPVRFZ-UHFFFAOYSA-M 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 210000003717 douglas' pouch Anatomy 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000008175 fetal development Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000002710 gonadal effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 208000003532 hypothyroidism Diseases 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000007233 immunological mechanism Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000013101 initial test Methods 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 229910052816 inorganic phosphate Inorganic materials 0.000 description 1
- 230000009027 insemination Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 238000002357 laparoscopic surgery Methods 0.000 description 1
- 238000002350 laparotomy Methods 0.000 description 1
- 230000003529 luteolytic effect Effects 0.000 description 1
- 230000001294 luteotrophic effect Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 210000004914 menses Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000010827 pathological analysis Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 239000002281 placental hormone Substances 0.000 description 1
- 210000005059 placental tissue Anatomy 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 239000012521 purified sample Substances 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000027272 reproductive process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000010079 rubber tapping Methods 0.000 description 1
- 238000013391 scatchard analysis Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 238000003307 slaughter Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012956 testing procedure Methods 0.000 description 1
- 229960001479 tosylchloramide sodium Drugs 0.000 description 1
- 208000006685 tubal pregnancy Diseases 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- G01N33/76—Human chorionic gonadotropin including luteinising hormone, follicle stimulating hormone, thyroid stimulating hormone or their receptors
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/807—Apparatus included in process claim, e.g. physical support structures
- Y10S436/808—Automated or kit
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/811—Test for named disease, body condition or organ function
- Y10S436/814—Pregnancy
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/815—Test for named compound or class of compounds
- Y10S436/817—Steroids or hormones
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/815—Test for named compound or class of compounds
- Y10S436/817—Steroids or hormones
- Y10S436/818—Human chorionic gonadotropin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Reproductive Health (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US05/522,760 US4016250A (en) | 1974-03-22 | 1974-11-11 | Method for testing for pregnancy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO753203L true NO753203L (zh) | 1976-07-21 |
Family
ID=24082227
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO753203A NO753203L (zh) | 1974-11-11 | 1975-09-19 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US4094963A (zh) |
| AT (1) | AT373396B (zh) |
| DE (1) | DE2548868C2 (zh) |
| DK (1) | DK420475A (zh) |
| NL (1) | NL7511109A (zh) |
| NO (1) | NO753203L (zh) |
| SE (2) | SE432485B (zh) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4560649A (en) * | 1981-10-15 | 1985-12-24 | Cornell Research Foundation | Assaying for hLH or hCG with immobilized hormone receptors |
| US4543339A (en) * | 1982-03-16 | 1985-09-24 | Oneill Christopher | Early pregnancy detection by detecting enhanced blood platelet activation |
| US4474891A (en) * | 1982-06-10 | 1984-10-02 | Warren Michelle P | Mini-iodinated polypeptide hormone tracer and method for its use |
| US4921808A (en) * | 1986-06-25 | 1990-05-01 | The Albany Medical College Of Union University | Method for determining follicle stimulating hormone |
| US5698448A (en) * | 1988-12-02 | 1997-12-16 | Soldin; Steven J. | Immunosuppressive drug binding proteins and use |
| FR2662804B1 (fr) * | 1990-06-01 | 1994-05-27 | Agronomique Inst Nat Rech | Anticorps polyclonaux anti-lh et leurs applications a la detection et/ou au dosage de la lh, chez de multiples especes animales. |
| US5786220A (en) * | 1995-04-28 | 1998-07-28 | Quidel Corporation | Assays and devices for distinguishing between normal and abnormal pregnancy |
| AU2558297A (en) * | 1996-05-16 | 1997-12-05 | Gynetics Inc. | Emergency contraceptive kit |
| US6182665B1 (en) * | 1997-06-02 | 2001-02-06 | Brigham And Women's Hospital | Maternal immune responsiveness as a predictor of pregnancy outcome |
| US6627457B2 (en) * | 2001-07-30 | 2003-09-30 | Quest Diagnostics Investments Incorporated | Methods for detecting pregnancy |
| WO2006021214A2 (en) * | 2004-08-24 | 2006-03-02 | Rådet For Agroindustri | A method and an apparatus for determining pregnancy of animals |
| ATE538217T1 (de) * | 2007-07-02 | 2012-01-15 | Univ Edinburgh | Erkennung von ektopischen schwangerschaften |
| ES2898778T3 (es) | 2016-07-21 | 2022-03-08 | ObsEva SA | Pautas posológicas de antagonistas de oxitocina para promover la implantación de embriones y prevenir aborto espontáneo |
| CA3149898A1 (en) | 2019-09-03 | 2021-03-11 | Ernest Loumaye | Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage |
| CN115380122A (zh) | 2020-02-10 | 2022-11-22 | 奥布赛瓦股份公司 | 用于催产素受体拮抗剂疗法的生物标志物 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3899298A (en) * | 1972-04-11 | 1975-08-12 | Squibb & Sons Inc | Method and apparatus for angiotensin i determination |
| US3988429A (en) * | 1975-04-16 | 1976-10-26 | The United States Of America As Represented By The United States Energy Research And Development Administration | Kit for the rapid preparation of 99m Tc red blood cells |
-
1975
- 1975-09-19 NO NO753203A patent/NO753203L/no unknown
- 1975-09-19 NL NL7511109A patent/NL7511109A/xx not_active Application Discontinuation
- 1975-09-19 SE SE7510554A patent/SE432485B/xx unknown
- 1975-09-19 DK DK420475A patent/DK420475A/da unknown
- 1975-10-31 DE DE2548868A patent/DE2548868C2/de not_active Expired
- 1975-11-10 AT AT0852575A patent/AT373396B/de not_active IP Right Cessation
-
1976
- 1976-05-20 US US05/688,277 patent/US4094963A/en not_active Expired - Lifetime
-
1979
- 1979-07-05 SE SE7905898A patent/SE437304B/sv unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DE2548868C2 (de) | 1984-09-13 |
| DE2548868A1 (de) | 1976-06-16 |
| SE7510554L (sv) | 1976-05-24 |
| NL7511109A (nl) | 1976-05-13 |
| SE437304B (sv) | 1985-02-18 |
| SE432485B (sv) | 1984-04-02 |
| US4094963A (en) | 1978-06-13 |
| ATA852575A (de) | 1983-05-15 |
| SE7905898L (sv) | 1979-07-05 |
| AT373396B (de) | 1984-01-10 |
| DK420475A (da) | 1976-07-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4016250A (en) | Method for testing for pregnancy | |
| Garth Sasser et al. | Detection of pregnancy by radioimmunoassay of a novel pregnancy-specific protein in serum of cows and a profile of serum concentrations during gestation | |
| NO753203L (zh) | ||
| Meyer et al. | Evidence of gonadal and gonadotropin antibodies in women with a suboptimal ovarian response to exogenous gonadotropin | |
| BRODY et al. | Immuno-assay of human chorionic gonadotropin in normal and pathologic pregnancy | |
| Nancarrow et al. | The early pregnancy factor of sheep and cattle | |
| Saxena et al. | Diagnosis and management of pregnancy by the radioreceptorassay of human chorionic gonadotropin | |
| Grudzinskas et al. | Circulating levels of pregnancy‐specific β1‐glycoprotein in early pregnancy | |
| Landesman et al. | Results of the first 1000 radioreceptorassays for the determination of human chorionic gonadotropin: a new, rapid, reliable, and sensitive pregnancy test | |
| CHENG | Development and characterization of a homologous radioimmunoassay for bovine follicle-stimulating hormone | |
| US5108897A (en) | Relaxin testing for early detection of pregnancy in dogs | |
| Allen | A quantitative immunological assay for pregnant mare serum gonadotrophin | |
| Sutherland et al. | Macropodid marsupial luteinizing hormone: validation of assay procedures and changes in concentrations in plasma during the oestrous cycle in the female tammar wallaby (Macropus eugenii) | |
| Edqvist et al. | Progesterone levels in the bovine peripheral plasma measured by the competitive protein binding technique | |
| Schneyer et al. | Radioimmunoassay of serum follicle-stimulating hormone and luteinizing hormone in the bottlenosed dolphin | |
| SANTORO et al. | Gonadotropin and inhibin concentrations in early pregnancy in women with and without corpora lutea | |
| Herrler et al. | Rapid milk progesterone assay as a tool for the selection of potential donor cows prior to superovulation | |
| Jackson et al. | Luteinizing hormone releasing activity in the hypothalamus of anestrous and cyclic ewes | |
| Haxton et al. | 'Unexplained infertility’results of secondary investigations in 95 couples | |
| Brewer et al. | Gestational trophoblastic disease: selected clinical aspects and chorionic gonadotropin test methods | |
| CA1081121A (en) | Plasma membrane extract from corpus luteum in pregnancy test | |
| Hay et al. | Two-hour assay for lutropin during ovulation. | |
| Khattab et al. | Serum follicle stimulating hormone levels in human pregnancy | |
| Canfield et al. | Measuring human chorionic gonadotropin for detection of early pregnancy loss | |
| El-Tomi et al. | Plasma human placental lactogen in late pregnancy and labor |